Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28184444 | 0.85 | HRH3 (0.61) | SMN1; SMN2POLBHRH3SIGMAR1TSHR | |
| SCHEMBL13293705 | 0.84 | POLB (1.00) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL24023501 | 0.84 | POLB (1.00) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL24023500 | 0.84 | POLB (1.00) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL30596563 | 0.84 | POLB (1.00) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL6795896 | 0.82 | POLB (0.96) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL7379184 | 0.82 | HRH3 (0.59) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL6568587 | 0.80 | POLB (0.62) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E | |
| SCHEMBL1005987 | 0.80 | FAAH (0.54) | SMN1; SMN2POLBHRH3SIGMAR1TSHR | |
| SCHEMBL31010162 | 0.79 | ALDH1A1 (0.72) | SMN1; SMN2POLBHRH3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| CN-102119163-A | Diazacarbazoles and methods of use | GENENTECH INC | 2011-07-06 | — | — | CN | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| EP-1910334-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | Exonhit Therapeutics SA (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | APP, BACE1, IAPP | SMN1; SMN2 1581/4885POLB 4268/4885HRH3 1139/4885 |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | SMN1; SMN2 3819/4885POLB 4770/4885HRH3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.